The maintenance of an Overweight rating suggests that Cantor Fitzgerald still sees Sanara MedTech as a good investment opportunity. However, the reduction in the price target could imply a reassessment of the company's growth prospects or market conditions, potentially leading to a neutral short-term impact on the stock price as investors digest the mixed signals.